Mineralys Therapeutics (MLYS) Competitors $14.21 +0.27 (+1.94%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock MLYS vs. RNA, ACLX, RARE, ZLAB, AKRO, MRUS, MOR, SRRK, PTGX, and CRNXShould you be buying Mineralys Therapeutics stock or one of its competitors? The main competitors of Mineralys Therapeutics include Avidity Biosciences (RNA), Arcellx (ACLX), Ultragenyx Pharmaceutical (RARE), Zai Lab (ZLAB), Akero Therapeutics (AKRO), Merus (MRUS), MorphoSys (MOR), Scholar Rock (SRRK), Protagonist Therapeutics (PTGX), and Crinetics Pharmaceuticals (CRNX). These companies are all part of the "pharmaceutical products" industry. Mineralys Therapeutics vs. Avidity Biosciences Arcellx Ultragenyx Pharmaceutical Zai Lab Akero Therapeutics Merus MorphoSys Scholar Rock Protagonist Therapeutics Crinetics Pharmaceuticals Mineralys Therapeutics (NASDAQ:MLYS) and Avidity Biosciences (NASDAQ:RNA) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, institutional ownership, risk, dividends, earnings, profitability and community ranking. Does the MarketBeat Community favor MLYS or RNA? Avidity Biosciences received 149 more outperform votes than Mineralys Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Mineralys Therapeutics an outperform vote while only 69.14% of users gave Avidity Biosciences an outperform vote. CompanyUnderperformOutperformMineralys TherapeuticsOutperform Votes19100.00% Underperform VotesNo VotesAvidity BiosciencesOutperform Votes16869.14% Underperform Votes7530.86% Do analysts rate MLYS or RNA? Mineralys Therapeutics currently has a consensus target price of $33.00, suggesting a potential upside of 138.18%. Avidity Biosciences has a consensus target price of $66.69, suggesting a potential upside of 112.43%. Given Mineralys Therapeutics' higher probable upside, analysts clearly believe Mineralys Therapeutics is more favorable than Avidity Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mineralys Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Avidity Biosciences 0 Sell rating(s) 0 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders and institutionals hold more shares of MLYS or RNA? 84.5% of Mineralys Therapeutics shares are owned by institutional investors. 33.2% of Mineralys Therapeutics shares are owned by company insiders. Comparatively, 3.7% of Avidity Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has more risk & volatility, MLYS or RNA? Mineralys Therapeutics has a beta of -0.39, meaning that its stock price is 139% less volatile than the S&P 500. Comparatively, Avidity Biosciences has a beta of 1.01, meaning that its stock price is 1% more volatile than the S&P 500. Does the media favor MLYS or RNA? In the previous week, Avidity Biosciences had 4 more articles in the media than Mineralys Therapeutics. MarketBeat recorded 11 mentions for Avidity Biosciences and 7 mentions for Mineralys Therapeutics. Avidity Biosciences' average media sentiment score of 1.60 beat Mineralys Therapeutics' score of 0.40 indicating that Avidity Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mineralys Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Avidity Biosciences 9 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Which has preferable earnings & valuation, MLYS or RNA? Mineralys Therapeutics has higher earnings, but lower revenue than Avidity Biosciences. Avidity Biosciences is trading at a lower price-to-earnings ratio than Mineralys Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMineralys TherapeuticsN/AN/A-$177.81M-$3.64-3.81Avidity Biosciences$10.90M346.34-$212.22M-$2.89-10.86 Is MLYS or RNA more profitable? Mineralys Therapeutics has a net margin of 0.00% compared to Avidity Biosciences' net margin of -2,772.45%. Avidity Biosciences' return on equity of -27.66% beat Mineralys Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Mineralys TherapeuticsN/A -67.97% -62.40% Avidity Biosciences -2,772.45%-27.66%-24.56% SummaryAvidity Biosciences beats Mineralys Therapeutics on 9 of the 16 factors compared between the two stocks. Get Mineralys Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MLYS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MLYS vs. The Competition Export to ExcelMetricMineralys TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$898.86M$6.79B$5.52B$7.83BDividend YieldN/A3.09%5.11%4.22%P/E Ratio-3.817.3322.4518.53Price / SalesN/A240.74393.51103.32Price / CashN/A65.8538.1834.62Price / Book3.616.396.754.24Net Income-$177.81M$142.94M$3.22B$248.05M7 Day Performance2.40%2.12%2.40%3.17%1 Month Performance-5.49%-1.62%-0.84%1.68%1 Year Performance13.10%1.67%17.85%5.93% Mineralys Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MLYSMineralys Therapeutics2.3831 of 5 stars$14.21+1.9%$33.00+132.2%+12.7%$921.89MN/A-3.9028Short Interest ↑High Trading VolumeRNAAvidity Biosciences2.8311 of 5 stars$28.52+7.0%$66.69+133.8%+30.2%$3.43B$10.90M-9.90190Positive NewsGap DownACLXArcellx1.8479 of 5 stars$60.93-1.8%$110.67+81.6%+26.6%$3.35B$107.94M-85.8280News CoveragePositive NewsRAREUltragenyx Pharmaceutical4.3349 of 5 stars$35.40-0.8%$92.79+162.1%-13.5%$3.32B$560.23M-5.581,310Upcoming EarningsShort Interest ↑News CoveragePositive NewsZLABZai Lab2.1668 of 5 stars$29.71+3.0%$47.37+59.4%+97.5%$3.26B$398.99M-10.731,950Positive NewsAKROAkero Therapeutics3.7743 of 5 stars$37.67+0.1%$76.29+102.5%+119.4%$3.00BN/A-10.0530Insider TradeNews CoveragePositive NewsMRUSMerus3.4301 of 5 stars$43.23+0.4%$85.31+97.3%-0.1%$2.99B$36.13M-10.9437Upcoming EarningsAnalyst ForecastShort Interest ↓Analyst RevisionNews CoveragePositive NewsMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730SRRKScholar Rock4.0415 of 5 stars$29.81-3.1%$42.67+43.1%+120.1%$2.83B$33.19M-12.69140Upcoming EarningsInsider TradeNews CoveragePositive NewsPTGXProtagonist Therapeutics3.422 of 5 stars$45.80-1.0%$65.44+42.9%+78.5%$2.81B$434.43M17.22120Upcoming EarningsNews CoveragePositive NewsCRNXCrinetics Pharmaceuticals3.6438 of 5 stars$30.15-0.9%$73.00+142.1%-24.3%$2.81B$1.04M-8.08210News CoveragePositive News Related Companies and Tools Related Companies RNA Competitors ACLX Competitors RARE Competitors ZLAB Competitors AKRO Competitors MRUS Competitors MOR Competitors SRRK Competitors PTGX Competitors CRNX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MLYS) was last updated on 4/30/2025 by MarketBeat.com Staff From Our PartnersTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredM.A.G.A. is Finished – This Could be even BetterYou’ve no doubt heard Trump’s rally cry: Make America Great Again. But recently the President made a big ch...Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredChina’s next move could destroy U.S. techThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mineralys Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mineralys Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MLYS Stock Free MLYS Stock Alerts